CHOP/Anthracycline Cumulative Dose Score Calculator

Clinical calculation support · Verify results before clinical use

Cumulative dose inputs

Enter the cumulative dose received for each listed anthracycline in mg/m². Enter zero if a drug was not used.

3Drug inputs
Conversion factor: 1.0 (reference drug).
Conversion factor: 0.6.
Conversion factor: 0.8.
Reset calculator

About doxorubicin-equivalent dose

This calculator estimates cumulative doxorubicin-equivalent exposure from the three listed agents. It is a dose-conversion aid, not a validated standalone cardiotoxicity score and not a substitute for a comprehensive cardio-oncology assessment.

Conversion method

AgentFactorCalculation
Doxorubicin1.0Dose × 1.0
Daunorubicin0.6Dose × 0.6
Epirubicin0.8Dose × 0.8

Formula: doxorubicin dose + (daunorubicin dose × 0.6) + (epirubicin dose × 0.8).

How to interpret the dose

ESC guidance uses cumulative doxorubicin-equivalent exposure as one part of risk assessment and monitoring. A cumulative dose of ≥250 mg/m² is a meaningful surveillance threshold in relevant settings; ≥250 and ≥400 mg/m² also appear in survivor risk frameworks. These bands do not determine an individual patient's risk by themselves.

References

Lyon AR, López-Fernández T, Couch LS, et al.

2022 ESC Guidelines on cardio-oncology. European Heart Journal. 2022;43(41):4229–4361.

doi:10.1093/eurheartj/ehac244

Swain SM, Whaley FS, Ewer MS.

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.

doi:10.1002/cncr.11407

The conversion ratios displayed here follow the ESC 2022 cardiovascular-toxicity dose ratio table. ESC notes that these isoequivalent ratios were derived from pediatric cancer-survivor data; applicability to every adult treatment context is not certain.

Clinical disclaimer: This calculator supports dose estimation only. Cardiotoxicity risk also depends on baseline cardiovascular disease and risk factors, age, prior chest radiotherapy, concomitant cardiotoxic therapies, treatment regimen, symptoms, biomarkers, and cardiac imaging. Use current oncology/cardio-oncology guidance and clinical judgement for monitoring and treatment decisions.